Omnicell (OMCL) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Omnicell

NasdaqGS•Healthcare•Health Information Services

$32.43-0.20(-0.01%)Pre-market

Market Cap

$1.49B

P/E

38.1x

P/S

1.2x

P/B

1.2x

Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

How this company scores

GoodMetricSide Score: 78/100

Strongest: Cash & Earnings Quality (25/25); weakest: Profitability (13/25).

Profitability13/25

Growth21/25

Balance Sheet & Red Flags19/25

Cash & Earnings Quality25/25

Strengths

Rising free cash flowRising earningsLow leverageCash-backed earnings

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 38.1x5y range 38.1x – 1005.6x

Currently below its 13-quarter median.

P/S · 1.2x5y range 1.2x – 7.1x

Currently below its 20-quarter median.

P/B · 1.2x5y range 1.0x – 7.0x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Price & Volume

Market Cap $1.49B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $1.25B
Q. Revenue: $312.21M
TTM EBITDA: $134.58M
TTM Op. Income: $57.96M
Q. Op. Income: $32.45M
TTM Net Income: $39.08M
Q. Net Income: $24.29M
EPS: $0.53
Shares Out.: $45.61M

$1.25B in TTM revenue grew 8.5% YoY, reaching $312.21M last quarter. TTM EBITDA of $134.58M and TTM operating income of $57.96M show growth is flowing through to the bottom line. TTM net income of $39.08M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 49.0%
EBITDA Margin: 16.4%
Op. Margin: 10.4%
Net Margin: 7.8%

Op. margin of 10.4% is up 7.6% YoY — cost efficiency is improving. Net margin at 7.8% and gross margin of 49.0% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 38.1x
P/S Ratio: 1.2x
P/B Ratio: 1.2x

At 38.1x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 1.2x and P/B of 1.2x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 7 quarters, P/E has fallen for 2 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $2.00B
Cash: $292.17M
Long-Term Debt: $168.20M
Book Value: $1.29B
D/E Ratio: 0.1
Debt/EBITDA: 3.3

With $2.00B in assets and $168.20M in long-term debt, D/E is 0.1and book value is $1.29B — a conservative capital structure with a cushion to weather downturns. Across the last 7 quarters, debt/equity has fallen for 3 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $68.31M
TTM Free Cash Flow: $142.60M
FCF Margin: 11.4%
FCF / Net Income: 3.6

TTM FCF of $142.60M on $68.31M in operating cash flow. The FCF / Net Income ratio of 3.6x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.